摘要
To develop the evidence-based guidelines for managing mother-to-child transmission of hepatitis B virus in China, a multidisciplinary guideline development group was estab-lished. Clinical questions were identified from two rounds of surveys on the concerns of first-line clinicians. We conducted a comprehensive search and review of the literature. A grading of recommendations' assessment, development, and evaluation system was adopted to rate the quality of evidence and the strength of recommendations. Recommen-dations were formulated based on the evidence, overall balance of benefits and harms (at individual and population levels), patient/health worker values and preferences, re-sources available, cost-effectiveness, and feasibility. Even-tually, recommendations related to 13 main clinical concerns were developed, covering diagnostic criteria, treatment in-dications, antiviral therapy choice, timing to initiate and discontinue treatment, immunoprophylaxis strategy at birth, and how to deal with special situations, such as unintended pregnancy, assisted reproduction, and breastfeeding. The guidelines are intended to serve as guidance for clinicians and patients, to optimize the management of majority of pregnant women who are positive for hepatitis B surface antigen. Guideline registration: International Practice Guide Registration Platform (IPGRP-2018CN040).
基金
This work was supported by Beijing Chen Jumei Foundation,Key R&D Program of Shaanxi(S2018-YF-ZDSF-0240)
National Natural Science Foundation of China Grants(81670537,81770594)
Chinese National Research Grant of the Thirteenth Five-Year Plan for Key Projects in Infectious Diseases(13th Five Year,China
Project No.2017ZX10202202-002006).The meeting expenses of the Guidelines Steering Committee and the Guidelines Development Panel were funded by Beijing Chen Jumei Foundation.
